By Jeff Buchanan, Xconomy
Mark Kubik, the company’s vice president of business development, says that some of the money will go toward fulfilling agreements it’s made with drug companies, including U.K.-based Oxford BioTherapeutics, which Invenra announced it had partnered with last year.
Invenra’s cell-free protein expression technology allows for the screening of hundreds of thousands of full antibodies, and is much faster than conventional cell-based methods for finding therapeutic antibodies.
The company’s core business model involves licensing its technology to drug makers, Kubik says. With these deals, the pharmaceutical partner owns and is responsible for developing the antibody products. Read more …